Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,502 result(s) found for: Cardiovascular diseases. Displaying page 7 of 126.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2018-003141-42 Sponsor Protocol Number: EX9924-4473 Start Date*: 2019-07-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Ongoing) CZ (Completed) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004115-12 Sponsor Protocol Number: 1002-050 Start Date*: 2017-05-17
    Sponsor Name:Esperion Therapeutics, Inc.
    Full Title: A Multicenter Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg
    Medical condition: Treatment of high cardiovascular risk patients (heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular diseases [ASCVD]) with hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    21.0 100000004861 10020667 Hyperlipidemia LLT
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002160-28 Sponsor Protocol Number: hepatology_MT_2005-05 Start Date*: 2005-09-23
    Sponsor Name:Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology
    Full Title: Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis
    Medical condition: Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essen...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000686-23 Sponsor Protocol Number: RAVE_v1 Start Date*: 2017-03-29
    Sponsor Name:Erasmus MC
    Full Title: The Rotterdam Antiplatelet Therapy in Vascular Patients Study
    Medical condition: myocardial injury in patients undergoing major vascular surgery, leading to (spontaneous) acute coronary syndrome and death through intracoronary plaque damage and subsequent thrombosis after major...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000046-19 Sponsor Protocol Number: RIVAROXHFA3001/BAY59-7939/16302 Start Date*: 2013-08-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Sub...
    Medical condition: Prevention of death, heart attack and stroke in patients with chronic heart failure and significant coronary artery disease following a hospitalization for exacerbation of heart failure.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) DE (Completed) NL (Completed) BG (Completed) PL (Completed) HU (Completed) SE (Completed) IT (Completed) GB (Completed) EE (Completed) LT (Completed) PT (Completed) DK (Completed) LV (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001401-25 Sponsor Protocol Number: QHD00012 Start Date*: 2019-09-27
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older
    Medical condition: Prevention of influenza infection in adults from 65 years of age and older
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000487-15 Sponsor Protocol Number: CLSYN.1702 Start Date*: 2018-12-21
    Sponsor Name:Hamilton Health Sciences Corporation through its Population Health Research Institute
    Full Title: CLEAR SYNERGY (OASIS 9) A 2x2 factorial randomized controlled trial of CoLchicine and spironolactonE in patients with ST elevation myocARdial infarction/SYNERGY Stent Registry – Organization to Ass...
    Medical condition: ST segment Elevation Myocardial Infarction (STEMI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) CZ (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002234-39 Sponsor Protocol Number: BAY59-7939/15693 Start Date*: 2012-08-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose...
    Medical condition: prevention of stroke and non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation scheduled for cardioversion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) ES (Completed) NL (Completed) DE (Completed) GR (Completed) BE (Completed) GB (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005740-27 Sponsor Protocol Number: 2019/ABM/01/00081 Start Date*: 2021-04-19
    Sponsor Name:Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
    Full Title: Effect of Intravenous FERRic carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with recent myocardial infarction
    Medical condition: Recent myocardial infarction associated with iron deficient
    Disease: Version SOC Term Classification Code Term Level
    27.1 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004853-59 Sponsor Protocol Number: EX6018-4758 Start Date*: 2021-08-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
    Medical condition: Atherosclerotic cardiovascular disease Chronic kidney disease Systemic inflammation
    Disease: Version SOC Term Classification Code Term Level
    26.0 10047065 - Vascular disorders 10051615 Atherosclerotic cardiovascular disease LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.1 10022891 - Investigations 10067394 hs-CRP increased LLT
    21.0 10022891 - Investigations 10011418 CRP increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000942-32 Sponsor Protocol Number: IZD334-002 Start Date*: 2020-07-16
    Sponsor Name:Inflazome Ireland Ltd.
    Full Title: A 12-week, multi-center, double-blinded, parallel-group, randomized, placebo-controlled phase IIb study to evaluate the safety, tolerability and efficacy of IZD334 to reduce CRP in cardiovascular h...
    Medical condition: Patients with stable coronary artery disease and high cardiovascular risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002266-40 Sponsor Protocol Number: CAIN457ADE02 Start Date*: 2013-12-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 ...
    Medical condition: active chronic plaque-type psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000516-42 Sponsor Protocol Number: CLX003-IMP-2-170121 Start Date*: 2018-03-20
    Sponsor Name:Cell Therapy Ltd (trading as Celixir)
    Full Title: A Phase IIB, Randomised, Double-Blinded, Placebo-Controlled Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human Immunomodulatory Progenitor (iMP) cells in Patients Und...
    Medical condition: Ischaemic heart disease post MI
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10048858 Ischaemic cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10023024 Ischaemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002243-98 Sponsor Protocol Number: 29702 Start Date*: 2011-09-12
    Sponsor Name:Department of Nephrology, OUH, Odense, DK
    Full Title: The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity
    Medical condition: Kidney graft failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10010185 Complications of transplanted kidney PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-005109-19 Sponsor Protocol Number: ATTICUS Start Date*: 2015-11-10
    Sponsor Name:University Hospital Tuebingen
    Full Title: Apixaban for treatment of embolic stroke of undetermined source
    Medical condition: Patients with embolic stroke of undetermined source and at least on risk factor for cardiac embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000441-32 Sponsor Protocol Number: REDOX2016 Start Date*: 2016-10-27
    Sponsor Name:Blekinge county council
    Full Title: REgistry-based randomized controlled trial of treatment Duration and mortality in long-term OXygen therapy (REDOX) A Multicenter, Phase III, Registry-Based, Randomized Controlled Trial (R-RCT)
    Medical condition: Chronic respiratory failure requiring LTOT (long-term oxygen treatment)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001053-44 Sponsor Protocol Number: Carotis-Rivaroxaban_CEUS_001 Start Date*: 2020-09-30
    Sponsor Name:Rigshospitalet, Department of Vascular Surgery
    Full Title: Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS)
    Medical condition: Patients with - Stable peripheral artery disease and - Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10075495 Internal carotid artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004959-80 Sponsor Protocol Number: IIS14005 Start Date*: 2017-08-01
    Sponsor Name:Special Account For Research Funds- National and Capodistrian University of Athens
    Full Title: A randomized, pharmacodynamic comparison of ticagrelor 60mg bid vs prasugrel 5mg in patients with prior myocardial infarction
    Medical condition: In this study we aim to compare the platelet inhibition of 60mg ticagrelor bid versus 5mg prasugrel in patients with prior myocardial infarction within previous 1-3 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005447-25 Sponsor Protocol Number: INTIMA Start Date*: 2013-02-22
    Sponsor Name:Academic Medical Center Amsterdam, department of Internal Medicine
    Full Title: The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque
    Medical condition: Atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 16:09:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA